Related Experiment Videos
[Anti-arrhythmic effect of cordaron in patients with unstable stenocardia and myocardial infarction]
Insights
Cordarone effectively treated unstable angina at 400-600 mg/day. However, higher doses (600 mg/day) were ineffective for myocardial infarction arrhythmia, and standard doses failed in subacute stages.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Arrhythmia is a common complication in cardiovascular diseases.
- Cordarone (amiodarone) is an antiarrhythmic drug.
- Optimal dosing for specific cardiac conditions requires investigation.
Purpose of the Study:
- To evaluate the antiarrhythmic efficacy of Cordarone in unstable angina and myocardial infarction.
- To determine effective dose regimens for Cordarone in these patient groups.
Main Methods:
- Prospective study involving patients with unstable angina and myocardial infarction.
- Administration of Cordarone in various dose regimens (400-600 mg/day and 200 mg/day).
- Monitoring of arrhythmia, including the number and frequency of extrasystoles.
Main Results:
- Cordarone (400-600 mg/day) showed significant efficacy in unstable angina pectoris.
- A 600 mg/day dose of Cordarone failed to significantly reduce arrhythmia in myocardial infarction.
- A 200 mg/day dose was insufficient to prevent arrhythmia progression in the subacute phase.
Conclusions:
- Cordarone dosing requires careful consideration based on the specific cardiac condition.
- Current standard dosing regimens may be inadequate for managing arrhythmia in myocardial infarction and subacute disease.
- Further research into optimized Cordarone therapy for different cardiovascular conditions is warranted.
Abstract:
Antiarrhythmic effect of cordaron in patients with unstable stenocardia (34) and transmural myocardial infarction (39) has been studied in various dose regimens. A dose of 400-600 mg/day was significantly effective in unstable angina pectoris, while in myocardial infarction a 600 mg/day dose failed to attenuate arrhythmia, i.e. the number and frequency of extra-systoles reduced insignificantly. In subacute disease a 200 mg/day cordaron could not prevent an increment of arrhythmia showing inadequacy of a standard scheme of the drug administration.